LUTS.COM Study – Evaluation and management of LUTS associated to BPH in the Context of Common Comorbidities

Sebastiano Spatafora1, Roberto Sanseverino2, Carlo Introini3, Lucia Simoni4, Giario Conti5
  • 1 Arcispedale S. Maria Nuova (Reggio Emilia)
  • 2 Ospedale Umberto I (Nocera Inferiore)
  • 3 Ospedale Evangelico Internazionale (Genova)
  • 4 Medineos Observational Research (Modena)
  • 5 Ospedale S. Anna (Como)

Objective

Patients with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostate Hypertrophy (BPH) frequently have comorbidities related to the cardiovascular system such as arterial hypertension, diabetes, hyperlipidemia and metabolic syndrome (1 – 8). In particular, BPH, causing nocturia- induced sleep disturbance, may have a possible impact on blood pressure variability during night- time (1). Patients with BPH also frequently complain of depression (9, 10), osteoarthritis (11) chronic renal disease (12), erectile dysfunction (2, 4, 7), and diabetes (13) and, finally they are frequently exposed to potentially hypotensive agents such as PDE5-inhibitors (14,15,16).
The pharmacological management of BPH with associated comorbidities is particularly complex with risk of multiple interactions among the different types of treatments (7, 14, 17, 18) and an high likelihood of early discontinuation of therapy; notwithstanding this, the impact of co-medications and comorbidities on therapeutic choice is still to be ascertained (19). In general, the evaluation of comorbidities is considered highly relevant for the management of patients with BPH (20).
1. Objective
The LUTS.COM (Evaluation and management of LUTS associated to BPH in the context of Common COMorbidities) observational study was designed to assess the prevalence of significant comorbidities in male patients attending a visit for LUTS associated with BPH at an outpatient clinical ward.
Moreover, the study aims (i) to describe the medications administered for comorbidities, (ii) to assess the patients’ quality of life patients by means of the nocturia-specific Quality-of-Life (N- QOL) questionnaire administered during the visit, and (iii) to describe the patients’ adherence to the anti-BPH medications as assessed by the Morisky 4-Item Self-Report Measure of Medication Adherence Scale (MMAS-4) (21, 22, 23), administered during the visit, in patients under pharmacologic treatment

Materials and Methods

The LUTS.COM study is an Italian, observational, multicenter, cross-sectional study endorsed by AURO.it (Associazione Urologi Ospedalieri).
At the enrolment visit, retrospective data such as diagnostic tests, and urological parameters (i.e. plasma levels of PSA, IPSS scores, Qmax, results of digital rectal examination or trans-rectal or suprapubic echographies) were collected up to 3 months earlier; moreover, data regarding comorbidities and pharmacological treatments for significant comorbidities and for LUTS were recorded. We focused on significant medical conditions such as arterial hypertension, known ischemic heart disease, known cerebrovascular disease, known peripheral arterial disease of lower limbs, diabetes mellitus, osteoporosis, major depressive disorder, chronic renal disorder, osteoarthritis, metabolic syndrome, and erectile dysfunction (as reported by patients). The patients’
To be considered as evaluable for the LUTS.COM study, patients had to be aged >= 50 years and present LUTS associated to BPH at enrolment as per clinical judgment. Patients who met the
following exclusion criteria were not considered as evaluable for the analyses: patients who received any investigational compound within 90 days prior to inclusion; patients who were immediate family members, study site employee, or in dependent relationship with a study site employee involved in the study; patients with known contra-indication to the medication prescribed for LUTS; patients who present or refer a known overactive bladder syndrome or prostate cancer.
quality of life was assessed by means of the N-QoL questionnaire. The N-QoL questionnaire (24) specifically measures the effect of nocturia on quality of sleep and consists of 12 items scored from 0 to 4 and one item regarding quality of life. Two sub-scales (sleep/energy and bother/concern) scores and an overall score can be calculated. Higher scores mean better quality of life. Finally, patients’ adherence to the anti-BPH therapies were evaluated by the MMAS-4. The MMAS-4 is a self-reported, medication-taking behavior scale and consists of four questions about the way patients might experience drug errors or omissions. The MMAS-4 score is a non- adherence score ranging from 0 to 4 (21, 22, 23); a higher score means higher adherence to therapy.

Results

Patients were consecutively enrolled from December 2014 to December 2015. The LUTS.COM study involved 29 Urology Italian Centers that enrolled 807 male patients. Final statistical analyses are currently ongoing.

Discussions

Data are not available yet. Statistical analyses will be performed in order to respond to the study objectives.

Conclusion

The management of patients with LUTS due to BPH is strongly influenced by the frequent presence of multiple comorbidities, and so, it is fundamental to have a clear idea of what is the distribution of comorbidities among these patients, in the Italian context. This study will allow to describe comorbidities in Italian patients affected by LUTS suggestive of BPH.

References

1. Karatas OF, Bayrak O, Cimentepe E, Unal D. An insidious risk factor for cardiovascular disease: benign prostatic hyperplasia. Int J Cardiol. 2010 Oct 29;144(3):452. doi: 10.1016/j.ijcard.2009.03.099. Epub 2009 Apr 9. PubMed PMID: 19359054.
2. Roehrborn CG, Nuckolls JG, Wei JT, Steers W; BPH Registry and Patient Survey Steering Committee. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int. 2007 Oct;100(4):813-9. PubMed PMID: 17822462.
3. Muzzonigro G. Tamsulosin in the treatment of LUTS/BPH: an Italian multicentre trial. Arch Ital Urol Androl. 2005 Mar;77(1):13-7. PubMed PMID: 15906783.
4. Li MK, Garcia L, Patron N, Moh LC, Sundram M, Leungwattanakij S, Pripatnanont C, Cheng C, Chi-Wai M, Loi-Cheong N. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int. 2008 Jan;101(2):197-202. Epub 2007 Nov 13. PubMed PMID: 18005205. McVary KT: BPH – epidemiology and comorbidities Am J Managed Care 2006, 12, 5 suppl.: S 122-8
5. Sarma AV, Kellogg Parsons J. Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr Urol Rep. 2009 Jul;10(4):267-75. Review. PubMed PMID: 19570487.
6. Shah M, Butler M, Bramley T, Curtice TG, Fine S. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population. Curr Med Res Opin. 2007 Feb;23(2):417-26. PubMed PMID: 17288695.
7. Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G; ALF-ONE Study Group. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol. 2006 Feb;175(2):624-8; discussion 628. PubMed PMID: 16407011.
8. Hartung R, Matzkin H, Alcaraz A, Emberton M, Harving N, van Moorselaar J, Elhilali M, Vallancien G; ALF-ONE Study Group. Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol. 2006 Feb;175(2):624-8; discussion 628. PubMed PMID: 16407011.
9. Quek KF, Low WY, Razack AH, Loh CS. The psychological effects of treatments for lower urinary tract symptoms. BJU Int. 2000 Oct;86(6):630-3. PubMed PMID: 11069367.
10. Rom M, Schatzl G, Swietek N, Rücklinger E, Kratzik C. Lower urinary tract symptoms and depression. BJU Int. 2012 Dec;110(11 Pt C):E918-21. doi: 10.1111/j.1464-
410X.2012.11552.x. Epub 2012 Oct 26. PubMed PMID: 23107188.
11. Song HJ, Han MA, Kang HC, Park KS, Kim KS, Kim MK, Kang J, Park EO, Hyun MY, Kim CS. Impact of lower urinary tract symptoms and depression on health-related quality of life in older adults. Int Neurourol J. 2012 Sep;16(3):132-8. doi: 10.5213/inj.2012.16.3.132. Epub 2012 Sep 30. PubMed PMID: 23094219; PubMed
Central PMCID: PMC3469832.
12. Hong SK, Lee ST, Jeong SJ, Byun SS, Hong YK, Park DS, Hong JY, Son JH, Kim C,
Jang SH, Lee SE. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2010 May;105(10):1424-8. doi: 10.1111/j.1464-410X.2009.08975.x. Epub 2009 Oct 28. PubMed PMID: 19874305.
13. Fourcade RO, Lacoin F, Rouprêt M, Slama A, Le Fur C, Michel E, Sitbon A, Cotté FE. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012 Jun;30(3):419-26. doi: 10.1007/s00345-011-0756-2. Epub 2011 Sep 3. PubMed PMID: 21892656; PubMed Central PMCID: PMC3360843.
14. White WB, Moon T. Treatment of benign prostatic hyperplasia in hypertensive men. J Clin Hypertens (Greenwich). 2005 Apr;7(4):212-7. Review. PubMed PMID: 15860960.
15. Nieminen T, Kööbi T, Tammela TL, Kähönen M. Hypotensive potential of sildenafil and tamsulosin during orthostasis. Clin Drug Investig. 2006;26(11):667-71. PubMed PMID: 17163302.
16. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005 Dec 26;96(12B):42M- 46M. Epub 2005 Dec 5. Review. PubMed PMID: 16387566.
17. Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology. 2003 Sep;62(3 Suppl 1):24-33. Review. PubMed PMID: 12957197.
18. O'Leary MP. Treatment and pharmacologic management of BPH in the context of common comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S129-40. Review. PubMed PMID: 16613527.
19. Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol. 2003 Nov;44(5):539-45. PubMed PMID: 14572751.
20. Djavan B, Margreiter M, Dianat SS. An algorithm for medical management in male lower urinary tract symptoms. Curr Opin Urol. 2011 Jan;21(1):5-12. doi: 10.1097/MOU.0b013e32834100ef. Review. PubMed PMID: 21045704.
21. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986 Jan;24(1):67-74. PubMed PMID: 3945130.
22. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2011 Mar;64(3):255-7; discussion 258-63. doi: 10.1016/j.jclinepi.2010.09.002. Epub 2010 Dec 8. PubMed PMID: 21144706; PubMed Central PMCID: PMC3109729.
23. Morisky DE, Malotte CK, Choi P, Davidson P, Rigler S, Sugland B, Langer M. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q. 1990 Fall;17(3):253-67. PubMed PMID: 2228629.
24. Abraham L, Hareendran A, Mills IW, Martin ML, Abrams P, Drake MJ, MacDonagh RP, Noble JG. Development and validation of a quality-of-life measure for men with nocturia. Urology. 2004 Mar;63(3):481-6. PubMed PMID: 15028442.

Argomenti: